Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 561-574

  Bornstein, Gadi Gazit ^a   Quéva, Christophe ^a   Tabrizi, Mohammad ^b   Van Abbema, Anne ^b   Chavez, Carlos ^b   Wang, Ping ^b   Foord, Orit ^b   Ahluwalia, Kiran ^b   Laing, Naomi ^a   Raja, Sandhya ^a   Wen, Shenghua ^a   Green, Larry L ^b   Yang, Xiaodong ^b   Webster, Carl ^c   Stewart, Ross ^c   Blakey, David ^a  

^a ASTRAZENECA   (United Kingdom)

^b AMGEN INC   (United States)

^c MEDIMMUNE   (United States)

Author keywords

ADCC; Antibody; Apoptosis; CD20; CDC; Lymphoma

Indexed keywords

CD16 ANTIGEN; CD20 ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY 1.5.3; RITUXIMAB; UNCLASSIFIED DRUG; CD20 ANTIGEN; MONOCLONAL ANTIBODY; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BIOTECHNOLOGY; BONE MARROW; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE DEPLETION; LYMPHOMA CELL LINE; MALE; MONKEY; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; EPITOPE MAPPING; IMMUNOLOGY; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MOLECULAR GENETICS; PATHOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPE MAPPING; HUMANS; LYMPHOMA, B-CELL; MACACA FASCICULARIS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; PEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77956062804     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9291-z     Document Type: Article

References (40)

1. P Stashenko LM Nadler R Hardy SF Schlossman 1980 Characterization of a human B lymphocyte-specific antigen J Immunol 125 1678 1685 1:STN:280: DyaL3M%2Fgsl2rtg%3D%3D 6157744
2. P Rosenthal IJ Rimm T Umiel, et al. 1983 Ontogeny of human hematopoietic cells: Analysis using monoclonal antibodies J Immunol 131 232 237 1:STN:280:DyaL3s3jvFygtw%3D%3D 6306100
3. LM Nadler SJ Korsmeyer KC Anderson, et al. 1984 B cell origin of non-T cell acute lymphoblastic leukemia: A model for discrete stages of neoplastic and normal pre-B cell differentiation J Clin Invest 74 332 340 10.1172/JCI111428 1:STN:280:DyaL2c3msFWrsQ%3D%3D 6378973
4. TF Tedder G Klejman SF Schlossman H Saito 1989 Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1) J Immunol 142 2560 2568 1:CAS:528:DyaK3cXhsFaktrg%3D 2466899
5. JK Riley MX Sliwkowski 2000 CD20: a gene in search of a function Semin Oncol 27 17 24 1:CAS:528:DC%2BD3MXitFCis7Y%3D 11225995
6. ME Reff K Carner KS Chambers, et al. 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 1:CAS:528:DyaK2cXhtVCnu70%3D 7506951
7. DG Maloney B Smith FR Appelbaum 1996 The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes anti-proliferative activity and induction of apoptosis Blood 88 637a
8. MA Ghetie EM Podar A Iigen BE Gordon JW Uhr ES Vitetta 1997 Homodimerization of tumor reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells PNAS 94 7509 7514 10.1073/pnas.94.14.7509 1:CAS:528:DyaK2sXksFyhur4%3D 9207122
9. DG Maloney AJ Grillo-Lopez CA White, et al. 1997 IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 2188 2195 1:CAS:528:DyaK2sXmtVOqsL0%3D 9310469
10. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma- half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
11. TA Davis AJ Grillo-Lopez CA White, et al. 2000 Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment J Clin Oncol 18 3135 3143 1:CAS:528:DC%2BD3cXntVCgsbo%3D 10963642
12. HT Chan D Hughes RR French, et al. 2003 CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts Cancer Res 63 5480 5489 1:CAS:528:DC%2BD3sXntleku7k%3D 14500384
13. MS Cragg MJ Glennie 2004 Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood 103 2738 2743 10.1182/blood-2003-06-2031 1:CAS:528:DC%2BD2cXjtVaksLc%3D 14551143
14. MS Cragg SM Morgan HT Chan, et al. 2003 Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood 101 1045 1052 10.1182/blood-2002-06-1761 1:CAS:528:DC%2BD3sXptVCjuw%3D%3D 12393541
15. DM Goldenberg EA Rossi R Stein TM Cardillo MS Czuczman FJ Hernandez-Ilizaliturri HJ Hansen CH Chang 2009 Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody Blood 113 1062 1070 10.1182/blood-2008-07-168146 1:CAS:528:DC%2BD1MXhvVajsLY%3D 18941114
16. JL Teeling RR French MS Cragg J van den Brakel, et al. 2004 Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood 104 1793 1800 10.1182/blood-2004- 01-0039 1:CAS:528:DC%2BD2cXns1Oktbc%3D 15172969
17. JL Teeling WJ Mackus LJ Wiegman J van den Brakel, et al. 2006 The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J Immunol 177 362 371 1:CAS:528:DC%2BD28XlvV2nt74%3D 16785532
18. P Umana E Moessner P Bruenker, et al. 2006 Novel 3 rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction ASH Annual Meeting Abstracts 108 229
19. MJ Mendez LL Green JR Corvalan, et al. 1997 Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice Nat Genet 15 146 156 10.1038/ng0297-146 1:CAS:528:DyaK2sXhtVOls7c%3D 9020839
20. A Jakobovits 1998 The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice Exp Opin Invest Drugs 7 607 614 10.1517/13543784.7.4.607 1:CAS:528:DyaK1cXislKms7s%3D
21. S Böttcher M Ritgen M Brüggemann T Raff S Lüschen A Humpe M Kneba C Pott 2005 Flow cytometric assay for determination of FcγRIIIA-158 V/F polymorphism J Immunol Methods 306 128 136 10.1016/j.jim.2005.08.004 16181633
22. ME Reff K Carner KS Chambers, et al. 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 1:CAS:528:DyaK2cXhtVCnu70%3D 7506951
23. MJ Polyak JP Deans 2002 Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure Blood 99 3256 3262 10.1182/blood.V99.9.3256 1:CAS:528:DC%2BD38XjtlGqs7k%3D 11964291
24. G Cartron L Dacheux G Salles P Solal-Celigny P Bardos P Colombat H Watier 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 754 758 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D 11806974
25. WK Weng R Levy 2003 Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 3940 3947 10.1200/JCO.2003.05.013 1:CAS:528:DC%2BD2cXpsVajsb8%3D 12975461
26. RL Shields AK Namenuk K Hong, et al. 2001 High resolution mapping of the binding site on human IgG1 for Fc-gamma-RI, Fc-gamma-RII, Fc-gamma-RIII, and FcRn and design of IgG1 variants with improved binding to the Fc-gamma-R J Biol Chem 276 6591 6604 10.1074/jbc.M009483200 1:CAS:528:DC%2BD3MXhslShurs%3D 11096108
27. F Ziller P Macor R Bulla D Sblattero R Marzari F Tedesco 2005 Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 Eur J Immunol 35 2175 2183 10.1002/eji.200425920 1:CAS:528:DC%2BD2MXmvVeju7k%3D 15971270
28. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B, & German Chronic Lymphocytic Leukemia Study Group 2001 Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 98 1326 1331 10.1182/blood.V98.5.1326
29. WA Hudson Q Li C Le JH Kersey 1998 Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects Leukemia 12 2029 2033 10.1038/sj.leu.2401236 1:STN:280:DyaK1M%2FlvFSltQ%3D%3D 9844934
30. F Bertolini L Fusetti P Mancuso A Gobbi C Corsini PF Ferrucci G Martinelli G Pruneri 2000 Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma Blood 96 282 287 1:CAS:528: DC%2BD3cXksVKjt7o%3D 10891463
31. C Schröder AM Azimzadeh G Wu JO Price JB Atkinson RN Pierson 2003 Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys Transpl Immunol 12 19 28 10.1016/S0966-3274(03)00059-5 14551029
32. Y Vugmeyster J Beyer K Howell, et al. 2005 Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis J Immunother 3 212 219 10.1097/01.cji.0000155050.03916.04
33. Y Vugmeyster K Howell K McKeever D Combs E Canova-Davis 2003 Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys Int Immunopharmacol 3 1477 1481 10.1016/S1567-5769(03)00147-4 1:CAS:528: DC%2BD3sXms1Oktro%3D 12946444
34. Q Gong Q Ou S Ye, et al. 2005 Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy J Immunol 174 817 826 1:CAS:528:DC%2BD2MXotFam 15634903
35. Y Vugmeyster K Howell A Bakshl C Flores E Canova-Davis 2003 Effect of anti-CD20 mAb, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix Cytometry 52A 101 109 10.1002/cyto.a.10030 1:CAS:528:DC%2BD3sXjt1yrtL8%3D
36. SP Treon C Mitsiades N Mitsiades G Young D Doss R Schlossman KC Anderson 2001 Tumor Cell Expression of CD59 is Associated with Resistance to CD20 Serotherapy in Patients with B-cell Malignancies J Immunother 24 263 271 10.1097/00002371-200105000-00011 1:CAS:528:DC%2BD3MXksVyhs7w%3D
37. R Bannerji I Flinn 2000 Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy Blood 96 164a
38. J Golay M Lazzari, et al. 2001 CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59 Blood 98 3383 3389 10.1182/blood.V98.12.3383 1:CAS:528:DC%2BD3MXovVSgsb8%3D 11719378
39. WK Weng R Levy 2001 Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 1352 1357 10.1182/blood.V98.5.1352 1:CAS:528:DC%2BD3MXmvFGjtrY%3D 11520782
40. T Alcindor TE Witzig 2002 Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma Curr Treat Options Oncol 3 275 282 10.1007/s11864-002-0027-y 12074764